Karp420
Posted - 2 days ago
$QTRX thank you lord for bringing this back down tomorrow is the day to start buying. Home run company
Pika_Capital
Posted - 2 days ago
$qtrx I don't get this. If you are desperate for cash and unload at these levels it's not like you can cash out immediately. Why not to wait until market opens tomorrow 🤡
IOMASS
Posted - 5 days ago
$QTRX Maybe some news expected tomorrow AM...
Pika_Capital
Posted - 5 days ago
Last week added a bit of $arwr $tgtx $zlab $qtrx
Bios will be back. Take advantage
IOMASS
Posted - 1 week ago
$QTRX Probably could use some internal news like an update on the testing network or licensing progress - but a key investor entering the picture would also be nice - the fact that QTRX will likely be in negotiations with various strategic parties re IP could produce some interesting results given low current valuation...
PeteFromPhilly
Posted - 1 week ago
$QTRX time to buy yet? They still have huge cash hoard? I recall this being at gift last year under 10 ...I left the party way too soon at $16-17 Did they miss eps or anything or just another random algo bear attack like were seeing in so many names?
Boomer52
Posted - 1 week ago
$QTRX Bottom in?
Miko_Vakilla
Posted - 1 week ago
$QTRX Bought in years ago at $8 and out at $20. Back in here.
IOMASS
Posted - 1 week ago
$QTRX New Cowen report is jibberish IMO - just lowering PT because stock is down - there will be competition but AD diagnostics and treatment is a huge market and QTRX will get a solid share of it - also, the stock price down here could make the company vulnerable to a strategic acquisition run, likely the reason for the new enhanced golden parachutes for CEO and CFO - plenty of ways to win on QTRX...
Swick02
Posted - 1 week ago
$QTRX taken to the woodshed, down 40% in just a few weeks. New tests continue to be announced, QTRX should get their fair share of the market. Current enterprise value of $300 million seems like this move has been a bit excessive. This will be a huge market. Added some more here at $16
Pika_Capital
Posted - 1 week ago
$QTRX ready to add another batch at these levels
IOMASS
Posted - 1 week ago
$QTRX Lots of recent news out there re AD to include new LLY/ROG diagnostic test and LH new neuro test - don't know if some of the news is being interpreted as negative for QTRX but I would think the developments are overall positive re the approaching sizeable market for AD diagnostics and therapy testing...
IOMASS
Posted - 1 week ago
$QTRX Some Speculation: Folks speculating re IP strength/ competition concerns but at least 2 analysts have recently reiterated @ $30+ PTs Pura Vida Investments owned 800+K shares EOY - speculation they are/have liquidated since QTRX has large cash position - could initiate buyback plan on weakness QTRX filed 8K late Friday disclosing an enhanced golden parachute for CEO n CFO upon a change of control event
jlwnh
Posted - 1 week ago
$QTRX @sogenerous curious your thoughts on this dip? 🙏
Swick02
Posted - 1 week ago
$QTRX competitive fears driving this decline, investors questioning the strength of the company’s IP position. I exited months ago in the mid-20’s, buying back here and selling puts.
LordThanaton
Posted - 2 weeks ago
$QTRX wow any news? Or just a healthy suprise?
Karp420
Posted - 2 weeks ago
$QTRX wow. QTRX going on sale. I missed this one and am happy to see it coming back. This is a great company. Will be scaling in for sure
LordThanaton
Posted - 2 weeks ago
$QTRX is it just me or anyone else liking these lvls?
IOMASS
Posted - 2 weeks ago
$QTRX Analysts reiterating $30+ PTs has had no great impact...volume not that big but price is silly given AD position
Pika_Capital
Posted - 2 weeks ago
@lowfloatscambuster has nothing to do with recent PR lol Look at ARKG. All life sciences tech is selling like crazy today $qtrx
lowfloatscambuster
Posted - 2 weeks ago
$QTRX The next time someone tells you companies don’t need seasoned IR and messaging people, remember this.
What a disaster
lowfloatscambuster
Posted - 1 month ago
$QTRX The correct answer to the question is:
“We will aggressively defend our intellectual property across all apllicable use cases. While we would prefer to reach mutually beneficial licensing agreements with interested parties, we will not hesitate to litigate if necessary. They need a real IR person. Desperately. Right now.
lowfloatscambuster
Posted - 1 month ago
$QTRX “Parties currently measuring Tau protein in relation to a neurological condition in a research or diagnostic setting on any other platform risk infringement of Quanterix’s intellectual property.”
👀👀👀
Stock_Titan
Posted - 1 month ago
$QTRX Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
https://www.stocktitan.net/news/QTRX/quanterix-outlines-partner-path-with-labs-to-expedite-building-xrnehxk2aeh8.html
TickerDD_com
Posted - 1 month ago
From 3/8/2024, looking back across 22 Month-Ends for QTRX, Percentage Change of Average Monthly Price had More Positives (77%) while Percentage Change of Average Monthly Volume had All Positives (100%) $QTRX #QTRX #QTRXStock #TickerDD https://www.youtube.com/watch?v=HPGsXjNb_d4
lowfloatscambuster
Posted - 1 month ago
$QTRX so we’re doing the labcorp news dance again with this.
https://www.prnewswire.com/news-releases/labcorp-launches-ptau217-blood-biomarker-test-to-accelerate-path-to-diagnosis-of-alzheimers-disease-and-support-clinical-trials-302094433.html
WantedToRetireEarly
Posted - 1 month ago
$QTRX from recent call:
For the full year, we expect GAAP gross margin to be in the 57% to 61% range and non-GAAP gross margin to be approximately 51% to 55%. As with revenue, this guide excludes margins from diagnostics testing. Lastly, on to capital allocation and cash usage. We expect our cash usage for the full year to be in the range of $25 million to $30 million and increase in cash usage of approximately $10 million at the midpoint. As Masoud mentioned, our priorities in 2024 will be growth in menu, innovation in tech and ramping up diagnostics. We will spend approximately $5 million to $10 million on the first two initiatives and approximately $10 million to $15 million on diagnostics with additional spend on diagnostics expected in 2025. This approximately $20 million investment in our strategic initiatives will be offset by approximately $10 million of reduced cash burn from revenue and margin growth.
DailyStocksPicks
Posted - 1 month ago
EyePoint Pharmaceuticals Inc. ($EYPT) appears undervalued after outperforming fourth-quarter earnings expectations and showing promising clinical trial results for EYP-1901. Despite a bearish sentiment due to revised revenue forecasts, the company's financial health and positive clinical outcomes suggest a potential market correction, making it a compelling consideration for investors looking for long-term value. $PACB, $QTRX, $CTKB, $LAB For More Details https://youtu.be/53IHP3Y7EFc
DailyStocksPicks
Posted - 1 month ago
Today’s pick number one is $CTKB. Cytek Biosciences Inc., a company that specializes in cell analysis solutions. Cytek has developed a cutting-edge technology known as Full Spectrum Profiling. Based in Fremont, California, it operates within the Medical - Biomedical and Genetics industry, which is ranked number 74 out of 252 by Zacks. Despite showcasing strong financial results and a positive outlook for FY 2024, CTKB might be considered oversold due to market reactions not fully reflecting its financial health and growth potential. This discrepancy could stem from broader market trends overshadowing the company's solid performance and future prospects. $EYPT, $QTRX, $PACB, $ALLO For more details https://youtu.be/cSfffj0OIas
WantedToRetireEarly
Posted - 1 month ago
$IBRX $QTRX $RNLX